Pharming Group N.V. presents its preliminary (unaudited) financial report for the second quarter and first half year ended June 30, 2024.

Second quarter 2024 total revenues increased by 35% to US$74.1 million, compared to the second quarter 2023, driven by strong RUCONEST® and Joenja® revenue growth
RUCONEST® second quarter revenue increased by 23% to US$63.0 million, compared to the second quarter 2023
Joenja® (leniolisib) second quarter revenue increased by 16% to US$11.1 million, compared to the first quarter 2024
First half total revenues increased by 33% to US$129.7 million, compared to the first half 2023
On track for 2024 total revenue guidance of US$280 million - US$295 million (14 - 20% growth)
Overall cash and marketable securities declined to US$161.8 million at the end of the second quarter 2024 from US$203.5 million at the end of the first quarter 2024, primarily due to convertible bond refinancing
Pharming to host a conference call today at 13:30 CEST (7:30 am EDT)
(view live webcast or register for the conference call)

see & read more on
https://www.pharming.com/news/pharming-group-reports-second-quarter-first-half-2024-financial-results